🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against superbug strains of the pathogen, according to health experts.

An International Challenge

Cases of gonorrhoea are on the rise globally, with figures suggesting more than 82 million infections each year. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

Zoliflodacin, also known as a brand name, was authorized by the US FDA in recent days for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in the same week. This medication, which is also used to treat UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This approval marks a major breakthrough in the management of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

Based on results published in a prominent scientific publication, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an equal footing with the current standard treatment, which combines two antibiotics. The trial enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in a wide range of developing nations.

Clinicians treating patients have shared hope. Having a single-dose, oral treatment like this is hailed as a "revolutionary step" for public health efforts. This is considered crucial to lessen the impact of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.